Perletti, 2016. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer 88.. https://doi.org/10.4081/aiua.2016.1.74